BEARINGPOINT
17.11.2022 08:06:39 CET | Business Wire | Press release
E-commerce trends induced by the global pandemic took online purchasing to the next level of development. This expansion led to significant changes for all online sales and logistics processes, including an increased need to optimize customer return-order processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005790/en/
In its recent client story, BearingPoint shows how it supported Kao, one of the leading global manufacturers of hair care products and cosmetics, in leveraging innovative technology to upgrade its return-order tasks.
Staying competitive in the fast-moving consumer goods (FMCG) market requires strong interconnectivity, real-time data transmission and reliable processes. In the past, managing an end-to-end process for return orders was labor-intensive and involved many employees, multiple IT devices and coordinating access to various software systems. Even when all these needs were met, the process often generated high costs and human errors in data entry along with strong dependencies.
The Kao Group aimed to leave this scenario behind and leverage innovation to gain efficiency. The company needed a better way to handle its return-order tasks, which at the time required a multi-step processing of documents and the input of data into SAP each time a request was received.
Management and technology consultancy BearingPoint worked with Kao to analyze the company’s existing processes to understand how its warehouse movements and activities – such as goods receiving, put away, storage and shipping – were translated into SAP system return-order data. A technical “to be” process was designed, which covered future workflow steps in detail, transaction loads, business rules, error handling, risks, dependencies and unknown exceptions.
Happy users and even more satisfied customers
“The RPA solution we used for Kao has made the company much more competitive. It not only automated the return order processes but freed up employees to do more value-added work. RPA solutions can benefit businesses in all industries, and it’s incredible how much they free up the workforce,” said Andreas Fitz, Partner at BearingPoint.
By leveraging UiPath’s RPA, BearingPoint developed a solution that formatted return-order email information automatically to create the required documents in SAP. The solution uses a bot first to extract relevant information – like original sales order, customer number, material code, and unrestricted and blocked quantities. It then immediately performs return orders, inbound delivery, and goods receipt transactions in SAP. The process is completed by sending out email notifications to Kao’s Customer Service department.
“With BearingPoint at our side, we were able to streamline and reduce a lot of manual work in a cumbersome internal process! Setting the bot solution live led to happy users and even more satisfied customers!” said Suyin Boehnke, SAP Senior Business Relationship Manager SCM EMEA, The Kao Group.
Kao can now process all its return-order tasks faster and more consistently, regardless of demand or data volume peaks. By using automation, the required documentation is processed 24/7 without significant interruptions or delays. The RPA solution provides transparent and accurate inventory data for further process improvements, such as stock and demand planning. Kao’s products that are eligible for resale are inserted into the marketplace workflow rapidly, thus reaching customers faster.
The company can now rely on an efficient process involving no additional interfaces, system access or need for human interaction, resulting in substantial cost optimization. The bot removes any risk of human error while freeing up time for Kao’s staff to work on other business-related, value-adding activities.
You can read the full client success story here: https://www.bearingpoint.com/en/insights-events/client-stories/kao-return-order-process-automation/
About Kao
Kao creates high-value-added products and services that provide care and enrichment for the lives of all people and the planet. Through its portfolio of over 20 leading brands – such as Oribe, Attack, Bioré, Goldwell, Jergens, John Frieda, Kanebo, Laurier, Merries and Molton Brown – Kao is part of the everyday lives of people in Asia, Oceania, North America, and Europe. Combined with its chemical business, which contributes to a wide range of industries, Kao generates about 1,420 billion yen in annual sales. Kao employs about 33,500 people worldwide and has 135 years of history in innovation.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005790/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
